1620 Investment Advisors, Inc. Biomarin Pharmaceutical Inc Transaction History
1620 Investment Advisors, Inc.
- $124 Million
- Q3 2024
A detailed history of 1620 Investment Advisors, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 1,348 shares of BMRN stock, worth $88,509. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,348
Previous 1,323
1.89%
Holding current value
$88,509
Previous $108,000
12.96%
% of portfolio
0.08%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding BMRN
# of Institutions
637Shares Held
177MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.49 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.27 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.24 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$913 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$689 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.2B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...